View More Recent Stories
-
Becton Dickinson (BDX) Tops Q4 EPS by 4c ; Offers Guidance
-
Becton Dickinson (BDX) Tops Q4 EPS by 4c; offers guidance
-
Becton Dickinson (BDX) Raises Quarterly Dividend 9.5% to $1.04; 1.7% Yield
-
Becton Dickinson (BDX) Launches Enhanced Intraosseous System
-
Becton Dickinson (BDX) Announces New Robotics Solution to Automate, Standardize Single-Cell Research
-
Becton Dickinson (BDX) Reaches Agreement to Resolve Vast Majority of Hernia Litigation
-
Citi Upgrades Becton Dickinson (BDX) to Buy
-
Becton Dickinson (BDX) Completes Acquisition of Critical Care from Edwards Lifesciences
-
Becton Dickinson (BDX) Appoints Michael Feld as President of Life Sciences Segment
-
Becton Dickinson (BDX) PT Lowered to $305 at Jefferies
-
Becton Dickinson (BDX) Tops Q3 EPS by 19c, provides guidance
-
Becton Dickinson (BDX) and Quest Diagnostics (DGX) Collaborate to Develop Companion Diagnostics for Cancer, Other Diseases
-
Becton Dickinson (BDX) Declares $0.95 Quarterly Dividend; 1.6% Yield
-
Becton Dickinson (BDX) Surpasses Scope 1 and 2 Reduction Milestones for FY 2023

